Skip to content

A large sample, multi-center randomized controlled trial of clinical efficacy of moxibustion combined with asthma in chronic duration

A large sample, multi-center randomized controlled trial of clinical efficacy of moxibustion combined with asthma in chronic duration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069775
Enrollment
Unknown
Registered
2023-03-24
Start date
2023-03-29
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic duration of bronchial asthma

Interventions

treatment group:Heat-sensitive moxibustion+Yiqi Wenyang Guard Tang
Control group:Seretide

Sponsors

Affiliated Hospital of Jiangxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of western medicine bronchial asthma; 2. Asthma stage is chronic and the severity of the disease is grade 2 or 3; 3. Within the two lateral lines of the bladder meridian on the dorsal foot, the area between the horizontal lines of Feishu point and Geishu point, or the area within the range of the first and second intercostal space of the anterior chest from inside to outside to 6 cun, acupoint heat sensitivity occurs. 4. Aged 18-65 years old; 5. The patient's consciousness was normal, and he could correctly express moxibustion sensation and cooperate in behavior. 6. Voluntarily take the test and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with other diseases that can cause asthma or dyspnea, such as bronchiectasis, pulmonary heart disease, pulmonary fibrosis, tuberculosis, pulmonary abscess, chronic obstructive pulmonary disease, etc. 2. Pregnant or lactating women; 3.patients with serious primary diseases of cardiovascular, hepatic, renal and hematopoietic systems, psychiatric patients and serious diseases affecting their quality of life; 4.Steroid-dependent patients or patients who had received systemic corticosteroid injections (intravenous, intramuscular, subcutaneous, or oral) within 4 weeks before enrollment; 5. Those who are intolerant to moxa smoke.

Design outcomes

Primary

MeasureTime frame
Asthma symptom score;

Secondary

MeasureTime frame
peak expiratory flow;Forced expiratory volume in one second;Frequency of asthma attacks;immunoglobulin E;

Countries

China

Contacts

Public ContactXue Hanlong/Xiong Jun

Affiliated Hospital of Jiangxi University of Chinese Medicine

xiongjun196071@163.com13970054277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026